WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414003
CAS#: 519187-23-6 (free base)
Description: Edonerpic Free Base is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
MedKoo Cat#: 414003
Name: Edonerpic Free Base
CAS#: 519187-23-6 (free base)
Chemical Formula: C16H21NO2S
Exact Mass: 291.1293
Molecular Weight: 291.41
Elemental Analysis: C, 65.95; H, 7.26; N, 4.81; O, 10.98; S, 11.00
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Edonerpic Free Base; T817; T 817; T-817
IUPAC/Chemical Name: 1-(3-(2-(Benzo(b)thiophen-5-yl)ethoxy)propyl)azetidin-3-ol
InChi Key: HQNACSFBDBYLJP-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H21NO2S/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2
SMILES Code: OC1CN(CCCOCCC2=CC=C3C(C=CS3)=C2)C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 291.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Moutal A, Shan Z, Miranda VG, François-Moutal L, Madura CL, Khanna M, Khanna R. Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels (Austin). 2019 Dec;13(1):498-504. doi: 10.1080/19336950.2019.1684608. PMID: 31680630; PMCID: PMC6833970.
2: Pines AR, Sattur MG, Abi-Aad KR, Bendok BR. Edonerpic Maleate: A Promising Pharmacological Agent for Stroke Recovery. Neurosurgery. 2019 Jan 1;84(1):E3-E4. doi: 10.1093/neuros/nyy397. PMID: 30551191.
3: Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer’s Disease Cooperative Study TCAD Study Group. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019 Nov 1;76(11):1330-1339. doi: 10.1001/jamaneurol.2019.1868. PMID: 31282954; PMCID: PMC6618817.
4: Abe H, Jitsuki S, Nakajima W, Murata Y, Jitsuki-Takahashi A, Katsuno Y, Tada H, Sano A, Suyama K, Mochizuki N, Komori T, Masuyama H, Okuda T, Goshima Y, Higo N, Takahashi T. CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage. Science. 2018 Apr 6;360(6384):50-57. doi: 10.1126/science.aao2300. PMID: 29622647.
5: Takahashi T. Novel synaptic plasticity enhancer drug to augment functional recovery with rehabilitation. Curr Opin Neurol. 2019 Dec;32(6):822-827. doi: 10.1097/WCO.0000000000000748. PMID: 31567431; PMCID: PMC6855342.
6: Khanna R, Moutal A, Perez-Miller S, Chefdeville A, Boinon L, Patek M. Druggability of CRMP2 for Neurodegenerative Diseases. ACS Chem Neurosci. 2020 Sep 2;11(17):2492-2505. doi: 10.1021/acschemneuro.0c00307. Epub 2020 Aug 4. PMID: 32693579.